Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInvestment IncomeNet Income - MinorityNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Tax ProvisionsTax Rate
Others
Ratios

Fresenius Medical Care AG (FMS) EBITDA: 2009-2024

Historic EBITDA for Fresenius Medical Care AG (FMS) over the last 16 years, with Dec 2024 value amounting to $1.5 billion.

  • Fresenius Medical Care AG's EBITDA rose 9.63% to $557.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 billion, marking a year-over-year decrease of 1.80%. This contributed to the annual value of $1.5 billion for FY2024, which is 0.44% up from last year.
  • As of FY2024, Fresenius Medical Care AG's EBITDA stood at $1.5 billion, which was up 0.44% from $1.5 billion recorded in FY2023.
  • Over the past 5 years, Fresenius Medical Care AG's EBITDA peaked at $2.6 billion during FY2020, and registered a low of $1.5 billion during FY2023.
  • Its 3-year average for EBITDA is $1.5 billion, with a median of $1.5 billion in 2024.
  • As far as peak fluctuations go, Fresenius Medical Care AG's EBITDA grew by 3.52% in 2020, and later dropped by 27.31% in 2022.
  • Fresenius Medical Care AG's EBITDA (MRY) stood at $2.6 billion in 2020, then fell by 16.69% to $2.2 billion in 2021, then fell by 27.31% to $1.6 billion in 2022, then fell by 7.03% to $1.5 billion in 2023, then increased by 0.44% to $1.5 billion in 2024.
  • Its EBITDA stands at $1.5 billion for FY2024, versus $1.5 billion for FY2023 and $1.6 billion for FY2022.